Literature DB >> 12377796

HCV infection should be managed in specialist centres.

G Dusheiko1.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 12377796      PMCID： PMC1773444          DOI： 10.1136/gut.51.5.625

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  8 in total

Review 1.  EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver.

Authors: 
Journal:  J Hepatol       Date:  1999-05       Impact factor: 25.083

2.  Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions.

Authors:  S Khakoo; P Glue; L Grellier; B Wells; A Bell; C Dash; I Murray-Lyon; D Lypnyj; B Flannery; K Walters; G M Dusheiko
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

Review 3.  Histopathology and detection of hepatitis C virus in liver.

Authors:  P J Scheuer; K Krawczynski; A P Dhillon
Journal:  Springer Semin Immunopathol       Date:  1997

Review 4.  National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C.

Authors: 
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

Review 5.  Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin.

Authors:  E Barnes; G Webster; R Jacobs; G Dusheiko
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

Review 6.  Natural history of hepatitis C.

Authors:  A Alberti; L Chemello; L Benvegnù
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

Review 7.  Pathology of hepatitis C virus infection.

Authors:  A P Dhillon; G M Dusheiko
Journal:  Histopathology       Date:  1995-04       Impact factor: 5.087

Review 8.  Recombinant alpha-interferon treatment of non-A, and non-B (type C) hepatitis: review of studies and recommendations for treatment.

Authors:  G L Davis
Journal:  J Hepatol       Date:  1990       Impact factor: 25.083
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.